Daniel Joseph O'Connell net worth and biography

Daniel O'Connell Biography and Net Worth

Chief Executive Officer of Acumen Pharmaceuticals

Daniel O’Connell has over 20 years of venture creation, venture investment and start-up operations experience with a focus on Neurosciences companies. He has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc. since December 2014. Under his leadership, Acumen has successfully transitioned from a privately-held, pre-clinical biotech company to a publicly-traded clinical-stage company developing a potential best-in-class treatment for early Alzheimer’s disease.

Mr. O’Connell previously co-founded and served as President and Chief Executive Officer of Functional Neuromodulation Ltd., a clinical-stage company developing deep brain stimulation therapies for Alzheimer’s disease. Mr. O’Connell is a founding member and former managing partner of NeuroVentures Capital, LLC, a firm he helped to invest in emerging neurosciences companies. He earned a B.A. from Brown University and M.B.A. from the University of Virginia.

What is Daniel Joseph O'Connell's net worth?: The estimated net worth of Daniel Joseph O'Connell is at least $1.97 million as of January 22nd, 2026. Mr. O'Connell owns 881,275 shares of Acumen Pharmaceuticals stock worth more than $1,974,056 as of August 5th. This net worth evaluation does not reflect any other assets that Mr. O'Connell may own. Learn More about Daniel Joseph O'Connell's net worth.
How do I contact Daniel Joseph O'Connell?: The corporate mailing address for Mr. O'Connell and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at [email protected]. Learn More on Daniel Joseph O'Connell's contact information.
Has Daniel Joseph O'Connell been buying or selling shares of Acumen Pharmaceuticals?: Daniel Joseph O'Connell has not been actively trading shares of Acumen Pharmaceuticals during the past quarter. Most recently, Daniel Joseph Oconnell sold 2,689 shares of the business's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $1.88, for a transaction totalling $5,055.32. Following the completion of the sale, the chief executive officer now directly owns 881,275 shares of the company's stock, valued at $1,656,797. Learn More on Daniel Joseph O'Connell's trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Marc Benioff (CEO), Nathan Fountain (Director), Paul Manning (Director), Daniel O'Connell (Chief Executive Officer), and John Stalfort, III (Director). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, insiders at the sold shares 30 times. They sold a total of 188,518 shares worth more than $374,717.53. The most recent insider tranaction occured on June, 17th when Director Derrell Porter sold 13,040 shares worth more than $30,383.20. Insiders at Acumen Pharmaceuticals own 10.2% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 6/17/2026.

Daniel Joseph O'Connell Insider Trading History at Acumen Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/22/2026	Sell	2,689	$1.88	$5,055.32	881,275
1/21/2026	Sell	9,346	$1.81	$16,916.26	883,964
1/12/2026	Sell	5,388	$1.73	$9,321.24	593,510
1/9/2026	Sell	12,941	$1.76	$22,776.16	598,898
1/8/2026	Sell	8,143	$1.82	$14,820.26	611,839
1/7/2026	Sell	37,755	$1.99	$75,132.45	619,982
1/6/2026	Sell	5,102	$1.97	$10,050.94	657,737
1/5/2026	Sell	4,649	$1.97	$9,158.53	662,839
1/21/2025	Sell	12,619	$1.59	$20,064.21	667,488
1/3/2025	Sell	47,778	$1.84	$87,911.52	454,707
1/19/2024	Sell	15,200	$3.47	$52,744.00	502,485

Daniel Joseph O'Connell Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $2.27

$2.22

$2.29

50 Day Range

MA: $2.37

$2.11

$2.77

2 Week Range

Now: $2.27

$1.19

$3.60

Volume

23,482 shs

Average Volume

605,192 shs

Market Capitalization

$163.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36